Refining the prognosis of breast cancer for personalised therapy

  • Research type

    Research Study

  • Full title

    Refining the prognosis of breast cancer and breast cancer precursor lesions for personalised therapy

  • IRAS ID

    266925

  • Contact name

    Andrew R Green

  • Contact email

    Andrew.Green@nottingham.ac.uk

  • Sponsor organisation

    University of Nottingham

  • Clinicaltrials.gov Identifier

    NA, NA

  • Duration of Study in the UK

    4 years, 11 months, 31 days

  • Research summary

    Over 56,000 women are diagnosed with breast cancer in the UK each year. Most patients have a type of breast cancer which responds well to current treatment choices and therefore survive longer. However, about a third of patients develop an aggressive form of breast cancer and can die earlier. Also, these forms of breast cancer do not respond well to drugs and in some patients they only treatment given work for a while. It is also hard to know which patients these are before they are treated and which will respond to certain treatment.\n\nThis proposal forms part of a long-term programme aimed at comprehensive characterisation of breast diseases to improve the diagnostic and treatment strategies. We aim to use different techniques to test the most likely candidate genes or proteins implicated in different molecular processes contributing to breast cancer progression that can be reliably used to predict outcome and response to therapy to help personalised approach of patient management. This will help breast cancer patients by identifying novel drug targets that can be used to stratify patients for management decisions and refine the use of systemic therapies and improve outcomes.\n\nIn order to do this, we aim to use breast tissue that has been donated for research from 8,000 breast cancer patients who have already been treated at Nottingham University Hospitals to study genes, proteins and the way the breast cancer cells look, and relate these to how aggressive their breast cancer was, whether they had a recurrence, died from breast cancer and what drugs they had. \n\nMost of the research will be conducted at the University of Nottingham by dedicated scientists. Some research will be conducted between us and other universities, hospitals and companies from all over the world.\n\nThe study will last for five years and is funded by several sources. As the patients have already donated their tissue for research they will not personally participate in the study or be contacted. \n

  • REC name

    Yorkshire & The Humber - Leeds East Research Ethics Committee

  • REC reference

    19/YH/0293

  • Date of REC Opinion

    23 Aug 2019

  • REC opinion

    Favourable Opinion